Liver disease in patients with transfusion-dependent β-thalassemia: The emerging role of metabolism dysfunction-associated steatotic liver disease

doi:10.4254/wjh.v16.i5.671

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (601)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

430

Sum=442

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=120

Publishing Process of This Article

Item

Count

Browse

Download

Sum=19

May 27, 2024 (publication date) through Jun 29, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Hepatol. May 27, 2024; 16(5): 671-677
Published online May 27, 2024. doi: 10.4254/wjh.v16.i5.671

Liver disease in patients with transfusion-dependent β-thalassemia: The emerging role of metabolism dysfunction-associated steatotic liver disease

Nikolaos Fragkou, Efthimia Vlachaki, Ioannis Goulis, Emmanouil Sinakos

Nikolaos Fragkou, Ioannis Goulis, Emmanouil Sinakos, 4^th Department of Internal Medicine, Hippokratio Hospital, Aristotle University of Thessaloniki, Thessaloniki 54642, Greece

Efthimia Vlachaki, 2^nd Department of Internal Medicine, Hippokratio Hospital, Aristotle University of Thessaloniki, Thessaloniki 54642, Greece

Author contributions: Fragkou N drafted the article; Vlachaki E, Goulis I and Sinakos E designed the study, made critical revisions related to important intellectual content of the manuscript and approved the final version of the study.

Conflict-of-interest statement: All authors have no conflict of interest to declare.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Emmanouil Sinakos, MD, PhD, Assistant Professor, 4^th Department of Internal Medicine, Hippokratio Hospital, Aristotle University of Thessaloniki, Konstantinoupoleos Str. 49, Thessaloniki 54642, Greece. em_sinakos@yahoo.com

Received: December 27, 2023
Revised: March 2, 2024
Accepted: April 17, 2024
Published online: May 27, 2024
Processing time: 146 Days and 20.2 Hours

Core Tip

Core Tip: Transfusion-dependent β-Thalassemia (TDBT) is one of the most frequent congenital diseases. Advances in the care of patients with TDBT over the past two decades have managed to significantly increase their life expectancy, making them more vulnerable to the onset of diseases related to the metabolic syndrome. Recent data from a relatively small study have highlighted the significance of the presence of hepatic steatosis in these patients. We herein discuss the available data concerning the presence of hepatic steatosis in this population, and the potential implications that these findings could have in the management of patients with TDBT, should these results be confirmed in larger cohorts.